Ann: HERIZON study results to be featured at ESMO Asia Congress, page-21

There is a good chance to get an early approval by the FDA after the current ph2 combo trials. All CAR-Ts have been approved on ph2 data according to CHM's CEO Jennifer Chow and that could apply to HER-Vaxx, as a brand new type of treatment, as well, results permitting of course.

That's the reason why IMU was so keen on doing these combo trials instead of going for a costly and time consuming ph3. But many had interpreted the combo trials and the rejection of inadequate partnering proposals as a " do it again due to failure ".

And that's why they are so keen on combo trials with CF 33 and approved treatments too.

IMU are the experts, we just have to let them do their fantastic job and not to take over ourselves.

GLTA